Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Apr;40(4):891–894. doi: 10.1128/aac.40.4.891

Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States.

G V Doern 1, M J Ferraro 1, A B Brueggemann 1, K L Ruoff 1
PMCID: PMC163225  PMID: 8849246

Abstract

Three hundred fifty-two blood culture isolates of viridans group streptococci obtained from 43 U.S. medical centers during 1993 and 1994 were characterized. Included were 48 isolates of "Streptococcus milleri," 219 S. mitis isolates, 29 S. salivarius isolates, and 56 S. sanguis isolates. High-level penicillin resistance (MIC, > or = 4.0 micrograms/ml) was noted among 13.4% of the strains; for 42.9% of the strains, penicillin MICs were 0.25 to 2.0 micrograms/ml (i.e., intermediate resistance). In general, amoxicillin was slightly more active than penicillin. The rank order of activity for five cephalosporins versus viridans group streptococci was cefpodoxime = ceftriaxone > cefprozil = cefuroxime >> cephalexin. The percentages of isolates resistant (MIC, > or = 2 micrograms/ml) to these agents were 15, 17, 18, 20, and 96, respectively. The rates of resistance to erythromycin, tetracycline, and trimethoprim-sulfamethoxazole were 12 to 38%. Resistance to either chloramphenicol or ofloxacin was uncommon (i.e., < 1%). In general, among the four species, S. mitis was the most resistant and "S. milleri" was the most susceptible.

Full Text

The Full Text of this article is available as a PDF (188.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bochud P. Y., Eggiman P., Calandra T., Van Melle G., Saghafi L., Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994 Jan;18(1):25–31. doi: 10.1093/clinids/18.1.25. [DOI] [PubMed] [Google Scholar]
  2. Bourgault A. M., Wilson W. R., Washington J. A., 2nd Antimicrobial susceptibilities of species of viridans streptococci. J Infect Dis. 1979 Sep;140(3):316–321. doi: 10.1093/infdis/140.3.316. [DOI] [PubMed] [Google Scholar]
  3. Dajani A. S., Bisno A. L., Chung K. J., Durack D. T., Freed M., Gerber M. A., Karchmer A. W., Millard H. D., Rahimtoola S., Shulman S. T. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA. 1990 Dec 12;264(22):2919–2922. [PubMed] [Google Scholar]
  4. Henslee J., Bostrom B., Weisdorf D., Ramsay N., McGlave P., Kersey J. Streptococcal sepsis in bone marrow transplant patients. Lancet. 1984 Feb 18;1(8373):393–393. doi: 10.1016/s0140-6736(84)90440-9. [DOI] [PubMed] [Google Scholar]
  5. Kern W., Kurrle E., Schmeiser T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection. 1990 May-Jun;18(3):138–145. doi: 10.1007/BF01642101. [DOI] [PubMed] [Google Scholar]
  6. Kern W., Linzmeier K., Kurrle E. Antimicrobial susceptibility of viridans group streptococci isolated from patients with acute leukemia receiving ofloxacin for antibacterial prophylaxis. Infection. 1989 Nov-Dec;17(6):396–397. doi: 10.1007/BF01645556. [DOI] [PubMed] [Google Scholar]
  7. McWhinney P. H., Gillespie S. H., Kibbler C. C., Hoffbrand A. V., Prentice H. G. Streptococcus mitis and ARDS in neutropenic patients. Lancet. 1991 Feb 16;337(8738):429–429. doi: 10.1016/0140-6736(91)91205-9. [DOI] [PubMed] [Google Scholar]
  8. McWhinney P. H., Patel S., Whiley R. A., Hardie J. M., Gillespie S. H., Kibbler C. C. Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin. Antimicrob Agents Chemother. 1993 Nov;37(11):2493–2495. doi: 10.1128/aac.37.11.2493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Quinn J. P., DiVincenzo C. A., Lucks D. A., Luskin R. L., Shatzer K. L., Lerner S. A. Serious infections due to penicillin-resistant strains of viridans streptococci with altered penicillin-binding proteins. J Infect Dis. 1988 Apr;157(4):764–769. doi: 10.1093/infdis/157.4.764. [DOI] [PubMed] [Google Scholar]
  10. Rapeport K. B., Girón J. A., Rosner F. Streptococcus mitis endocarditis. Report of 17 cases. Arch Intern Med. 1986 Dec;146(12):2361–2363. [PubMed] [Google Scholar]
  11. Roberts R. B., Krieger A. G., Schiller N. L., Gross K. C. Viridans streptococcal endocarditis: the role of various species, including pyridoxal-dependent streptococci. Rev Infect Dis. 1979 Nov-Dec;1(6):955–966. doi: 10.1093/clinids/1.6.955. [DOI] [PubMed] [Google Scholar]
  12. Venditti M., Baiocchi P., Santini C., Brandimarte C., Serra P., Gentile G., Girmenia C., Martino P. Antimicrobial susceptibilities of Streptococcus species that cause septicemia in neutropenic patients. Antimicrob Agents Chemother. 1989 Apr;33(4):580–582. doi: 10.1128/aac.33.4.580. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES